CJC-1295 vs Epithalon
Head-to-head comparison of CJC-1295 and Epithalon for research applications. Both peptides are studied for Anti-Aging, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Epithalon |
|---|---|---|
| Category | Growth Hormone Secretagogue | Anti-Aging / Telomere |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | Epithalon (C14H22N4O9, MW ~390 daltons) activates telomerase, particularly the catalytic subunit TERT (telomerase reverse transcriptase), extending telomeres at chromosome ends. |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Research-only / No approved human indication in Western countries |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Generally well tolerated; no serious adverse events reported in decades of Russian clinical use; Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 5–10 mg/day SC |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~390.3 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | Several hours |
Overview
CJC-1295 and Epithalon are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Epithalon — Mechanism & Evidence
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW ~390 g/mol) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism involves telomerase activation to maintain telomere length. Secondary mechanisms include melatonin enhancement via pineal gland restoration, hormonal balance improvement, and antioxidant defense. Extensive Russian research spanning 20+ years of clinical use reports safety and efficacy, but Western clinical trials remain minimal. Animal studies show lifespan extension of up to 13.3% in the last 10% of survivors (p<0.05).
Key claims: Activates telomerase and extends telomeres; Extends lifespan in animal models; Restores melatonin production and sleep quality.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
Epithalon is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Epithalon: Generally well tolerated; no serious adverse events reported in decades of Russian clinical use Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported Mild headaches, dizziness, and GI discomfort possible
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe